115.14 0.00 (0.00%)
After hours: 4:35PM EDT
|Bid||110.00 x 100|
|Ask||117.85 x 400|
|Day's Range||114.78 - 116.94|
|52 Week Range||83.01 - 153.15|
|PE Ratio (TTM)||-145.38|
|Earnings Date||Oct 31, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||148.61|
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
Incyte stands out among biotech companies chasing next-generation treatments that work with patients' own immune systems to combat cancer.
Incyte Corporation announced today that it has scheduled its third quarter financial results conference call and webcast for 10:00 a.m. ET on Tuesday, October 31, 2017.
Incyte Corporation and Cancer Support Community Delaware today announced the establishment of the Incyte Cancer Care Assistance Fund for Delaware which will provide emergency financial assistance for cancer patients, their caregivers and family members living in Delaware.